Back to Results
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
||Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
||Michael Kelly, MD
- To find out if subjects with down syndrome and standard risk acute myeloid leukemia can be treated with less treatment and still have successful outcomes.
- To find out if subjects with down syndrome and high risk acute myeloid leukemia can be successfully treated with stronger chemotherapy.
- Children with down syndrome (trisomy 21)
- Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome
- No prior treatment for leukemia
Subjects will come to the hospital to receive courses of chemotherapy. Usually, all subjects with DS AML get the same amount of chemo. In this study, subjects that respond to the first course of chemo will be given less chemo in later courses in the hope of reducing side effects. And subjects that do not respond to the first course of chemo will be given more chemo in later courses in the hope of improving outcomes.